Novartis (NOVN) PT Set at CHF 91 by Cfra

Cfra set a CHF 91 price target on Novartis (VTX:NOVN) in a research report sent to investors on Tuesday, March 27th. The firm currently has a buy rating on the stock.

NOVN has been the topic of a number of other research reports. Morgan Stanley set a CHF 92 price target on Novartis and gave the stock a buy rating in a report on Friday, December 1st. JPMorgan Chase set a CHF 84 price target on Novartis and gave the stock a neutral rating in a report on Friday, December 29th. Credit Suisse Group set a CHF 77 target price on Novartis and gave the company a neutral rating in a research note on Wednesday, January 24th. Barclays set a CHF 80 target price on Novartis and gave the company a sell rating in a research note on Thursday, January 25th. Finally, Jefferies Group set a CHF 95 target price on Novartis and gave the company a buy rating in a research note on Monday, February 26th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of CHF 88.50.

How to Become a New Pot Stock Millionaire

Shares of NOVN traded up CHF 0.34 on Tuesday, reaching CHF 78.38. The stock had a trading volume of 11,210,000 shares, compared to its average volume of 5,980,000. Novartis has a twelve month low of CHF 72.45 and a twelve month high of CHF 88.30.

ILLEGAL ACTIVITY WARNING: “Novartis (NOVN) PT Set at CHF 91 by Cfra” was first published by Macon Daily and is the property of of Macon Daily. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://macondaily.com/2018/04/12/novartis-novn-pt-set-at-chf-91-by-cfra-updated-updated.html.

About Novartis

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply